KAZIA THERAPEUTICS LTD

KAZIA THERAPEUTICS LTD Annual Report Summary: Plain Talk for Investors

Let’s cut through the noise and see how Kazia Therapeutics—a small cancer drug developer—performed this year, and whether it’s worth your investment attention.

---

What Happened This Year?

The Short Version: A mixed bag. Their lead drug, paxalisib (for aggressive brain cancers), showed early promise, but their backup drug failed. They’re now “all in” on paxalisib.

Key Details:

• Paxalisib Progress: Early trial data looked encouraging for glioblastoma (a deadly brain cancer). Started new trials for childhood brain tumors.
• Cantrixil Failure: Their ovarian cancer drug failed a Phase 3 trial. They’ve stopped work on it entirely.
• New CEO: Dr. John Friend, a cancer drug veteran, took over in early 2023.

---

Financial Health: Can They Stay Afloat?

• Cash: $8.1 million left (down from $12.5 million last year).
• Monthly Burn Rate: ~$1.5 million.
• Runway: About 5 months of cash left at current spending. Expect another fundraising round soon (likely selling more shares, which could dilute existing investors).
• Revenue: Almost none ($0.1 million vs. $1.2 million last year). They rely on partnerships and investor cash.

---

Wins vs. Setbacks

✅ Good News:

• FDA granted paxalisib “Fast Track” status (speeds up reviews if trials succeed).
• Partnered with St. Jude’s Hospital and others to share trial costs.
• Early patient data showed paxalisib might extend survival for tough cancers.

❌ Bad News:

• Cantrixil failure wasted time and money.
• Stock price dropped ~30% this year.
• Still 2-3 years away from potential FDA approval (if everything goes perfectly).

---

Big Risks to Know

1. Trial Failure Risk: Paxalisib is their only drug now. If it flops, the stock could crash.
2. Cash Crunch: They’ll likely need to raise more money soon, which could dilute shares.
3. Competition: Big Pharma companies are working on similar drugs with more resources.

---

Should You Invest? The Straight Talk

Potential Upside:

• If paxalisib succeeds in trials, Kazia could be a buyout target (big payday for shareholders).
• Brain cancer treatments are urgently needed—success could mean blockbuster sales.

Downside Warnings:

• High risk of dilution (more shares = your ownership % shrinks).
• Biotech trials fail often—this is a speculative bet, not a stable investment.
• The company provided limited details on long-term strategy beyond 2024.

---

The Bottom Line

For Risk-Tolerant Investors Only. Kazia is a binary bet:

• If paxalisib’s 2024 trial data is strong, the stock could multiply.
• If trials disappoint or cash runs out, the stock could drop sharply.

Watch Closely:

• Trial updates in 2024 (make-or-break moment).
• Any announcements about new funding or partnerships.
• Signs of progress in childhood brain tumor trials.

Investing in Kazia is like backing a single rocket launch—it could reach orbit or crash on the pad. Don’t invest money you can’t afford to lose.

---

This summary reflects the company’s disclosed annual performance. Always do your own research before investing.